miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

NEXT STORY
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
PREV STORY
Zomedica to Voluntarily Delist its Common Shares from TSX Venture Exchange Effective February 10, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure

author_avatar
NASDAQ Market News

Neovacs to present at two major Investor Conferences:

PARIS and BOSTON, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader ...

author_avatar
NASDAQ Market News

Medicenna Therapeutics to Present at Upcoming September Investor Conferences

author_avatar
NASDAQ Market News